Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-08-25
1990-12-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514403, 514404, 514419, 514423, 514428, 514467, 514471, 514481, 514484, 514488, 514510, 514530, 514562, 514563, 546323, 548342, 548372, 548495, 548539, 548567, 549229, 549487, 560 10, 560 12, 560 13, 560 27, 560 28, 560 38, 560 39, 560 41, 560115, 560118, 562427, 562430, 562443, 562444, 562450, 562500, A61K 31195, A61K 3124, C07C22910
Patent
active
049754440
ABSTRACT:
Compounds of the formula ##STR1## wherein A is a carbocyclic, saturated or unsaturated ring; R.sup.1 is hydrogen or alkyl; R and R.sup.4 are each alkyl, cycloalkyl, benzyl or a readily hydrolyzable ester group; Y is a bond or a straight or branch alkylene; R.sup.2 is hydrogen, aryl, heterocyclic, R.sup.6 CONR.sup.5, R.sup.7 NR.sup.5 CO, R.sup.7 NR.sup.5 SO.sub.2 --or R.sup.8 SO.sub.2 NR.sup.5 --where R.sup.5 is hydrogen, alkyl or aralkyl; R.sup.6 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group of the formula ##STR2## where R.sup.9 is hydrogen, hydroxy, alkoxy, alkyl, hydroxyalkyl, aralkyl, alkylene, heterocyclic, heterocyclylalkyl, R.sup.12 CONH--, R.sup.12 SO.sub.2 NH-- or (R.sup.13).sub.2 N--; R.sup.10 and R.sup.11 are each hydrogen or alkyl; or R.sup.10 is hydrogen and R.sup.11 is aminoalkyl, imidazolylmethyl, aryl, aralkyl, aralkoxyalkoxy, hydroxyalkyl or methylthioalkyl; or R.sup.10 and R.sup.11 together with the carbon to which they are attached form a carbocyclic or heterocyclic ring optionally substituted by amino, alkanoyl or aroyl; R.sup.12 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; each R.sup.13 is hydrogen, alkyl, aralkyl or both R.sup.13 together with the nitrogen to which they are attached form a heterocyclic ring; R.sup.7 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group ##STR3## where R.sup.10 and R.sup.11 are as defined and R.sup.14 is (R.sup.13).sub.2 NCO, R.sup.12 OCH.sub.2 -- or R.sup.15 OCO, where R.sup.12 and R.sup.13 are as defined and R.sup.15 is alkyl, cycloalkyl or aralkyl; and R.sup.8 is alkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; R.sup.3 is a group ##STR4## where R.sup.16 is hydrogen, halo, hydroxy, alkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyloxy, cycloalkoxycarbonylalkoxy or alkyl SO.sub.2 NH--; and R.sup.20 is hydrogen, alkyl, alkoxy, alkanoyl or halo; or R.sup.3 is 3-indolylmethyl or 3-indazolylmethyl, each optionally substituted in the benzenoid ring by alkyl, alkoxy, hydroxy or trifluoromethyl as antihypertensive agents.
Danilewicz John C.
James Keith
Kobylecki Ryszard J.
Lumb J. Trevor
Olson A. Dean
Pfizer Inc.
Raymond Richard L.
Richardson Peter C.
LandOfFree
Cycloalkyl-substituted glutaramide antihypertensive agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl-substituted glutaramide antihypertensive agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl-substituted glutaramide antihypertensive agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-883666